0
The	  FDA	  Guidance	  of	  Risk-­‐Based	  Approach	  to	  Monitoring	  as	  Viewed	                  From	  CDM	         ...
Agenda	  InteracEons:	  Sponsors,	  Clinical	  OperaEons	  and	  CDM	  Risk-­‐Based	  Monitoring	      –  Challenges	  for...
TradiEonal	  Paper-­‐Based	  Work-­‐Flow	  Pa#ent	  Data	                 Database	  	                    	  
Data	  Flow	  &	  Monitoring:	  The	  Future	                           Centralized	            CRACRC                    ...
SupporEng	  Risked-­‐Based	  Monitoring	  –	        Challenges	  for	  Sponsors	  •  “The	  most	  important	  tool	  for	...
SupporEng	  Risked-­‐Based	  Monitoring	  –	    Challenges	  in	  Clinical	  OperaEons	  •  Trial	  specific	  •  Describe	...
SupporEng	  Risked-­‐Based	  Monitoring	  –	            Challenges	  in	  CDM	  •  Centralized	  Monitoring	  •  Quality	 ...
Data	  Quality/Integrity	  •  IdenEfy	  criEcal	  study	  data	  and	  processes,	  e.g.	      –    Endpoints	      –    S...
Role	  or	  Skill	  Set	  Adjustments	  Needed	   to	  Support	  Risked-­‐Based	  Monitoring	  •  Sponsors	  •  Site	  Coo...
Summary	  •  From	  the	  perspecEve	  of	  CDM	      –  Need	  coordinaEon	  in	  planning	  across	  funcEonal	         ...
                              	                   William	  Gluck,	  Ph.D.	  VP,	  DATATRAK	  Clinical	  and	  ConsulEng	 ...
Upcoming SlideShare
Loading in...5
×

CDM's Role in Supporting Risk-Based Monitoring

882

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
882
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
15
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Transcript of "CDM's Role in Supporting Risk-Based Monitoring"

  1. 1. The  FDA  Guidance  of  Risk-­‐Based  Approach  to  Monitoring  as  Viewed   From  CDM   Presented  By   William  Gluck,  PhD   VP,  DATATRAK  Clinical  and  ConsulEng  Services   DATATRAK  InternaEonal,  Inc.        
  2. 2. Agenda  InteracEons:  Sponsors,  Clinical  OperaEons  and  CDM  Risk-­‐Based  Monitoring   –  Challenges  for  Sponsors   –  Challenges  for  Monitors   –  Challenges  for  CDM  ImplementaEon  –  Will  there  be  any  affect  on  data   quality  or  integrity?  Will  the  Risked-­‐Based  Approach  require  roles/skill  set   adjustments?  
  3. 3. TradiEonal  Paper-­‐Based  Work-­‐Flow  Pa#ent  Data   Database      
  4. 4. Data  Flow  &  Monitoring:  The  Future   Centralized   CRACRC Database     CDM
  5. 5. SupporEng  Risked-­‐Based  Monitoring  –   Challenges  for  Sponsors  •  “The  most  important  tool  for  ensuring  human   subject  protecEon  and  high-­‐quality  data  is  a  well-­‐ designed  and  arEculated  protocol.”  •  Guidance  intends  to  assist  sponsors  in  developing   risk-­‐based  monitoring  strategies  and  plans   –  Tailored  to  the  specific  human  subject  protecEon  and  data   integrity  risks  of  the  trial   –  Focuses  on  criEcal  study  parameters   –  Encourages  use  of  a  combinaEon  of  monitoring  acEviEes   –  Encourages  greater  reliance  on  centralized  monitoring   pracEces,  where  appropriate  –  it  is  OK  not  to  do  100%  SDV  
  6. 6. SupporEng  Risked-­‐Based  Monitoring  –   Challenges  in  Clinical  OperaEons  •  Trial  specific  •  Describe  monitoring  methods,  responsibiliEes,  and   requirements  •  Components  to  consider   –  DescripEon  of  monitoring  approaches  (e.g.,  Eming,   intensity,  acEviEes,  documentaEon)  –  Targeted  SDV   –  CommunicaEon  of  monitoring  results   –  Management  of  noncompliance   –  Training  and  study-­‐specific  informaEon   –  Monitoring  plan  amendments  
  7. 7. SupporEng  Risked-­‐Based  Monitoring  –   Challenges  in  CDM  •  Centralized  Monitoring  •  Quality  and  Integrity  Checks   –  Increased  checks   –  Increased  data  collecEon  •  Technologically  Few  Challenges  •  Process/Workflow  Flow  –  KEY!    
  8. 8. Data  Quality/Integrity  •  IdenEfy  criEcal  study  data  and  processes,  e.g.   –  Endpoints   –  Serious  Adverse  Events   –  RandomizaEon/  Blinding   –  Consent   –  Eligibility  Criteria   –  Risks  specific  to  protocol  design  and  conduct  •  Perform  and  document  a  risk  assessment  to  idenEfy  risks   to  these  criEcal  data  and  processes  •  Design  plans  tailored  to  address  important  and  likely   risks  idenEfied  during  risk  assessment  
  9. 9. Role  or  Skill  Set  Adjustments  Needed   to  Support  Risked-­‐Based  Monitoring  •  Sponsors  •  Site  Coordinators/Staff  •  CRAs/Monitors   –  Increases  in  support  and  technology  skills  •  CDM   –  Increases  in  technology  process   –  Increases  in  training  skills  
  10. 10. Summary  •  From  the  perspecEve  of  CDM   –  Need  coordinaEon  in  planning  across  funcEonal   groups/departments   –  No  overwhelming  hurdles  to  implementaEon  •  Guidance  reflects  acknowledgment  that   changes  to  the  clinical  trial  enterprise  are  OK  •  Process  integraEon  is  key  to  efficient  use  of   resources  and  to  add  quality  
  11. 11.     William  Gluck,  Ph.D.  VP,  DATATRAK  Clinical  and  ConsulEng  Services   Datatrak  InternaEonal,  Inc.   Phone:  919-­‐651-­‐0222   Cell:  919-­‐522-­‐9681   E-­‐Mail:  Bill.Gluck@datatrak.net  
  1. Gostou de algum slide específico?

    Recortar slides é uma maneira fácil de colecionar informações para acessar mais tarde.

×